| Company Name: |
AdooQ BioScience, LLC
|
| Tel: |
+1 (866) 930-6790 |
| Email: |
info@adooq.com |
| Products Intro: |
Product Name:HIF-C2
CAS:1422955-31-4
Purity:98% Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
|
| | 2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitro- Basic information |
| Product Name: | 2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitro- | | Synonyms: | 2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitro-;HIF-C2;HIF-2 Antagonist 2;N-(3-Chloro-5-fluorophenyl)-4-nitrobenzo[c][1,2,5]oxadiazol-5-amine;HIF-2 inhibitor 2;HIF Inhibitor VII - Calbiochem;TC-S 7009;N-(3-Chloro-5-fluorophenyl)-4-nitro-2,1,3-benzoxadiazol-5-amine | | CAS: | 1422955-31-4 | | MF: | C12H6ClFN4O3 | | MW: | 308.6524432 | | EINECS: | | | Product Categories: | | | Mol File: | 1422955-31-4.mol |  |
| | 2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitro- Chemical Properties |
| Boiling point | 430.2±55.0 °C(Predicted) | | density | 1.652±0.06 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: soluble15mg/mL, clear | | form | Yellow powder | | pka | -2.82±0.48(Predicted) | | color | white to beige | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 1 month. |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 |
| | 2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitro- Usage And Synthesis |
| Description | HIF-2α-I2 (1422955-31-4) is a potent and selective HIF-2α inhibitor, Kd=81 nM.1?Binds to the HIF-2α PAS-B domain2?and interferes with Hif-2α / ARNT heterodimerization reducing target gene expression in a cellular model1. Highly selective for HIF-2α displaying a >60-fold selectivity over HIF-1α.1,2 | | Uses | N-(3-Chloro-5-fluorophenyl)-4-nitro-2,1,3-benzoxadiazol-5-amine is a HIF-2α inhibitor which inhibits HIF-2α-ARNT heterodimerization by binding to HIF-2α PAS-B domain. It may be used in therapeutic treatment of HIF-2-driven tumors such as renal cell carcinomas. | | storage | Store at RT | | References | 1) Scheuermann?et al.?(2013),?Allosteric inhibition of hypoxia inducible factor-2 with small molecules; Nat. Chem. Biol.,?9?271
2) Masetti?et al.?(2014),?Protein dynamics of the HIF-2α PAS-B domain upon heterodimerization and ligand binding; PLoS One,?9(4)?e94986
3) Rodgers?et al.?(2013),?Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor; J. Med. Chem.,?56 1739 |
| | 2,1,3-Benzoxadiazol-5-aMine, N-(3-chloro-5-fluorophenyl)-4-nitro- Preparation Products And Raw materials |
|